

1102865-0047

IN THE CLAIMS:

Please cancel claims 1-5, 7, 8, 9, 13 and 14 without prejudice. Please consider the following amended claims:

A3 6. The synthetic immunogen of claim 17, wherein the promiscuous epitope is selected from the group consisting of a sequence of TT, DT, Malarial Protein-CSP, and MSP-F.

10. The synthetic immunogen of claim 17 wherein the spacer peptide is selected from the group consisting of Gly-Pro-Ser-Leu (SEQ ID NO: 5 in the Sequence Listing), Ser-Ser-Gly-Pro-Ser-Leu (SEQ ID NO: 6 in the Sequence Listing), and Ser-Ser-Gly-Pro-Ser-Leu-Lys-Leu (SEQ ID NO: 7 in the Sequence Listing).

A4 11. The synthetic immunogen of claim 17 wherein the fusion peptide is selected from the group consisting of the peptide defined by SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20.

12. The synthetic immunogen of claim 17 wherein the fusion peptide is selected from the group consisting of one or more than one peptide defined by SEQ ID NO: 10 and SEQ ID NO: 11.

A5 15. A pharmaceutical injectable composition comprising the synthetic immunogen as claimed in claim 17, and a pharmaceutically acceptable carrier.

Please consider the new claims 17-22.

17. A synthetic immunogen for inducing specific antibodies against GnRH comprising a promiscuous helper T-lymphocyte epitope fused through a spacer peptide to a GnRH immunomimic peptide comprising either an amino acid sequence of SEQ ID NO: 1, or a 2-10 amino acid sequence portion of SEQ ID NO: 1.

A6 18. The synthetic immunogen of claim 17 wherein the promiscuous helper T-lymphocyte epitope is fused through a spacer peptide to the amino-terminus and/or carboxy-terminus of the GnRH-immunomimic peptide.

1102865-0047

-- 19. The synthetic immunogen of claim 17 wherein the promiscuous helper T-lymphocyte epitope is fused through a spacer peptide to the amino-terminus of the GnRH-immunomimic peptide.--

-- 20. The synthetic immunogen of claim 17 comprising an acetylated amino-terminus and/or an amidated carboxy-terminus.--

-- 21. A combination of synthetic immunogens for inducing specific antibodies against GnRH comprising:

(i) a fusion peptide as defined by SEQ ID NO: 10; and

(II) a fusion peptide as defined by SEQ ID NO: 11; so as to store and use it separately or together in a mixture.--

-- 22. A pharmaceutical injectable composition comprising at least two different synthetic immunogens of anyone of the claims 11, 12 and 21, and a pharmaceutically acceptable carrier.--